Patents Examined by Sarvamangala Devi
  • Patent number: 10722569
    Abstract: Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins. Some aspects of this disclosure provide compositions and methods useful for the generation of vaccines and the vaccination of subjects, for delivering molecules of interest to a target site, for example, a surface, for purification of molecules of interest, for example, from bioreactors comprising engineered bacteria as provided herein, and for bioremediation applications, such as the cleanup of environmental pollutants.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: July 28, 2020
    Assignee: Children's Medical Center Corporation
    Inventor: Paula I. Watnick
  • Patent number: 10688120
    Abstract: The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 23, 2020
    Assignee: NITTO DENKO CORPORATION
    Inventors: Kyohei Matsushita, Masahiro Fukasaka, Takuya Shishido, Daisuke Asari, Katsuyuki Okubo, Mitsuhiko Hori
  • Patent number: 10682398
    Abstract: Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: June 16, 2020
    Assignees: THE TEXAS A&M UNIVERSITY SYSTEM, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Olivia B. Faulkner, Lisa Bielke, Leona Nicole Calhoun, Luc Berghman, Billy Hargis
  • Patent number: 10681932
    Abstract: The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: June 16, 2020
    Assignee: INTERNATIONAL NUTRITION RESEARCH COMPANY
    Inventor: Claude Vincent
  • Patent number: 10682377
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: June 16, 2020
    Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Patent number: 10668142
    Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 2, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Paolo Costantino
  • Patent number: 10668143
    Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: June 2, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
  • Patent number: 10654901
    Abstract: Microorganisms with increased photosynthetic capacity are described. Increased photosynthetic capacity is achieved by down-regulating activity of the RpaB pathway. The microorganisms include Cyanobacteria, including genetically-modified Cyanobacteria.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 19, 2020
    Assignees: Lumen Bioscience, Inc., Reliance Holding USA, Inc.
    Inventors: James Roberts, Damian Carrieri, Mark Heinnickel
  • Patent number: 10656153
    Abstract: Devices, solutions and method capable of quantifying a clinically significant amount of antibodies within a plasma sample obtained from an individual by quantifying binding between antibodies within the sample and microbial proteins are disclosed.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 19, 2020
    Assignee: PZM DIAGNOSTICS, LLC
    Inventor: Peilin Zhang
  • Patent number: 10653763
    Abstract: The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is F. psychrophilum and/or infectious pancreatic necrosis virus (IPNV).
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: May 19, 2020
    Assignee: BENCHMARK ANIMAL HEALTH LIMITED
    Inventors: Elizabeth Mary Crump, Jan Burian, Joseph Michale Bricker, William Wayne Kay, Norman William Johnson
  • Patent number: 10646521
    Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: May 12, 2020
    Assignees: INSTITUT GUSTAVE ROUSSY, UNIVERSITÉ PARIS—SACLAY, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT DE LA RECHERCHE AGRONOMIQUE
    Inventors: Laurence Zitvogel, Ivo Gomperts Boneca, Patricia Lepage, Sophie Viaud, Romain Daillere
  • Patent number: 10632157
    Abstract: The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial ensembles, and compositions comprising the same, in methods for modulating the production of poultry, disease resistance, and egg yield. In particular aspects, the disclosure provides methods of increasing feed efficiency, and methods of preventing colonization of pathogenic microbes.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: April 28, 2020
    Assignee: Ascus Biosciences, Inc.
    Inventors: Mallory Embree, Grant Gogul, Cameron Martino, Norm Pitt
  • Patent number: 10624366
    Abstract: The disclosure relates to methods for decreasing feed conversion ratios in fowl through administering isolated microorganisms to the fowl. In particular aspects, the disclosure provides methods of decreasing feed conversion ratios in fowl through administration of a Bacillus sp. to the fowl. The disclosure further relates to isolated microorganisms and compositions comprising the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: April 21, 2020
    Assignee: Ascus Biosciences, Inc.
    Inventors: Mallory Embree, Grant Gogul, Cameron Martino, Norm Pitt
  • Patent number: 10617121
    Abstract: Strains of Chromobacterium sphagni sp. nov. are described which have insecticidal activity against insect larvae, in general, and lepidopteran insect larvae, in particular. A biocontrol agent containing one or more C. sphagni, media in which the C. sphagni, or both, and optionally a carrier are also described. Methods of killing insect larvae and methods of reducing insect populations in an area by applying to the area or an object an effective amount of the biocontrol agent are also described.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: April 14, 2020
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Michael B. Blackburn, Dawn E. Gundersen-Rindal, Robert R. Farrar, Daniel J. Kuhar
  • Patent number: 10617134
    Abstract: The disclosure relates to isolated microorganisms-including novel strains of the microorganisms-microbial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production of poultry, disease resistance, and egg yield. In particular aspects, the disclosure provides methods of increasing feed efficiency, and methods of preventing colonization of pathogenic microbes.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: April 14, 2020
    Assignee: Ascus Biosciences, Inc.
    Inventors: Mallory Embree, Grant Gogul, Cameron Martino, Norm Pitt
  • Patent number: 10617766
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: April 14, 2020
    Assignee: Sanofi Pasteur Inc.
    Inventor: Robert P. Ryall
  • Patent number: 10603377
    Abstract: Provided are a composition and a food or drink, having the effect of enhancing an immune response to an antigen, which is administered by another route such as subcutaneous injection, by orally administering to a subject, lactic acid bacteria, a culture thereof, a treated product thereof, or a composition comprising the same. An oral ingestion composition, which comprises a lactic acid bacterium strain that is Lactococcus lactis subsp. lactis enhancing the proliferation of cytotoxic T lymphocytes (CTL) and the generation of antibodies, or a culture or treated product thereof, and is used in combination with an antigen as a vaccine, wherein the oral ingestion composition is for use in enhancing the proliferation of cytotoxic T lymphocytes (CTL) specific to the antigen and the generation of antibodies specific to the antigen.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: March 31, 2020
    Assignee: Kirin Holdings Kabushiki Kaisha
    Inventors: Hiroaki Suzuki, Kenta Jounai, Daisuke Fujiwara
  • Patent number: 10603354
    Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: March 31, 2020
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, ACTINOBAC BIOMED, INC.
    Inventors: Scott C. Kachlany, Benjamin A. Belinka, Jr.
  • Patent number: 10596206
    Abstract: Provided herein are probiotic compositions and methods to enhance bacterial diversity in the intestinal tract of a subject. A probiotic is provided comprising lymphoid tissue-resident commensal bacteria, and optionally IL-10, IL-22, and/or hepcidin. The probiotic can be used to promote intestinal health or to treat or prevent intestinal disease or condition.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 24, 2020
    Assignee: Cornell University
    Inventors: Gregory F. Sonnenberg, Nicholas J. Bessman
  • Patent number: 10596246
    Abstract: The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. The compositions are adjuvanted with an aluminium phosphate adjuvant.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 24, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICAL SA
    Inventors: Beatrice Maria Arico, Brunella Brunelli, Maurizio Comanducci, Mariagrazia Pizza, Silvana Savino, Maria Scarselli